600511.SH
国药股份
SSE · Healthcare · Medical - Distribution · CN
CNY 26.26
−0.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 53.3B | 52.5B | 50.6B | 49.7B | 45.5B |
| Cost of Revenue | 49.8B | 49.0B | 47.0B | 45.7B | 41.7B |
| Gross Profit | 3.5B | 3.5B | 3.6B | 4.0B | 3.8B |
| Operating Expenses | |||||
| R&D Expense | 68.3M | 69.3M | 73.7M | 71.2M | 67.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 468.0M | 465.5M | 461.5M | 467.1M | 435.6M |
| Selling & Marketing Expense | 716.9M | 724.5M | 805.1M | 962.4M | 956.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.4B | 1.4B | 1.5B | 1.5B |
| Cost and Expenses | 51.2B | 50.4B | 48.4B | 47.2B | 43.2B |
| Operating Income (EBIT) | 2.6B | 2.6B | 2.7B | 2.9B | 2.7B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 2.6B | 2.6B | 2.7B | 2.9B | 2.7B |
| Income Tax Expense | 505.2M | 510.7M | 523.8M | 596.4M | 559.2M |
| Bottom Line | |||||
| Net Income | 2.0B | 2.0B | 2.0B | 2.1B | 2.0B |
| Earnings from Cont. Ops | 2.1B | 2.1B | 2.1B | 2.3B | 2.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.0B | 2.0B | 2.0B | 2.1B | 2.0B |
| Per Share | |||||
| Basic EPS | CN¥2.67 | CN¥2.65 | CN¥2.65 | CN¥2.84 | CN¥2.60 |
| Diluted EPS | CN¥2.67 | CN¥2.65 | CN¥2.65 | CN¥2.84 | CN¥2.60 |
| Revenue Per Share | CN¥70.66 | CN¥69.54 | CN¥67.06 | CN¥65.87 | CN¥60.30 |
| Shares | |||||
| Basic Shares Outstanding | 754.5M | 754.5M | 754.5M | 754.5M | 754.5M |
| Diluted Shares Outstanding | 754.5M | 754.5M | 754.5M | 754.5M | 754.5M |
| Profitability Metrics | |||||
| EBITDA | — | 2.8B | 2.8B | 3.1B | 2.8B |
| D&A | — | 137.7M | 128.2M | 121.7M | 111.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026